Lv4
606 积分 2022-12-30 加入
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC With R1 Resection Margins: A Real-World Analysis
1个月前
已关闭
Real-World Efficacy and Safety of Adjuvant Third-Generation EGFR-TKIs in Elderly Patients Aged ≥75 Years With Resected EGFR-Mutant NSCLC
1个月前
已关闭
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
1个月前
已完结
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
1个月前
已完结
Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian network meta-analysis
1个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer
1个月前
已完结
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
1个月前
已完结
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
1个月前
已完结
皖公网安备34019202002308
